Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration
News Mar 11, 2014
This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China. Biomarkers from PBI complement WuXi's own biomarker capabilities. PBI has a leading position in biomarkers for cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.
"We are very pleased to reach this agreement with Pacific Biomarkers, which broadens WuXi's biomarker capabilities in support of our clients' clinical development," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Biomarkers are a new and important tool in the development of personalized medicines for many serious diseases."
"Partnering with WuXi enables us to realize considerable value in our biomarker assets," said Ronald Helm, CEO of Pacific Biomarkers. "This agreement will allow us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China."